Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

FDA Updates

News

Video Game Treatment for Adults With ADHD Cleared by FDA
News
Video Game Treatment for Adults With ADHD Cleared by FDA
07/02/2024
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults...
07/02/2024
Psych Congress Network
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
News
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
06/11/2024
Evi Arthur
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma,...
06/11/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
: FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
News
FDA Approves Oral Valbenazine Granule Formulation, an Alternative Administration Option for Adults With TD
05/15/2024
Evi Arthur
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine Biosciences, Inc. announced the approval of INGREZZA® SPRINKLE (valbenazine) capsules by the FDA. This approval provides an alternative option for patients with dysphagia or who have difficulty swallowing. 
At the end of April, Neurocrine...
05/15/2024
Psych Congress Network
FDA approval stamp
News
FDA Approves First Prescription Digital Therapeutic for Adjunctive Major Depressive Disorder Treatment
04/30/2024
Meagan Thistle
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as the first prescription digital therapeutic for the treatment of MDD symptoms as an adjunct to clinician-managed outpatient care for adult patients.
Rejoyn has been FDA approved as...
04/30/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network
FDA
News
FDA Preliminary Evaluation Finds No Clear Link Between GLP-1 Drugs and Suicidal Thoughts, Cautions on Small Risk
01/26/2024
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation of GLP-1 RAs found no evidence that the medications cause suicidal drugs or actions but cautions that a small risk cannot yet be ruled out.
The FDA's preliminary evaluation...
01/26/2024
Psych Congress Network
FDA headquarters
News
FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment
10/27/2023
Meagan Thistle
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed...
10/27/2023
Psych Congress Network
FDA building
News
FDA Approves First Oral Postpartum Depression Treatment, Zuranolone
08/07/2023
Meagan Thistle
The FDA approved Zurzuvae (zuranolone) on Friday through a fast-track designation, making it the first oral medication designed for the treatment of PPD in adults.
The FDA approved Zurzuvae (zuranolone) on Friday through a fast-track designation, making it the first oral medication designed for the treatment of PPD in adults.
The FDA approved Zurzuvae...
08/07/2023
Psych Congress Network
Video Game Treatment for Adults With ADHD Cleared by FDA
News
Video Game Treatment for Adults With ADHD Cleared by FDA
07/02/2024
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults...
07/02/2024
Psych Congress Network
Age-Dependent Association Found Between Cannabis Use and Psychosis
News
Age-Dependent Association Found Between Cannabis Use and Psychosis
06/27/2024
Cannabis use was significantly associated with psychotic disorders during adolescence, but not during young adulthood, according to results from an observational study published in Psychological Medicine. 
Cannabis use was significantly associated with psychotic disorders during adolescence, but not during young adulthood, according to results from an observational study published in Psychological Medicine. 
Cannabis use was significantly...
06/27/2024
Psych Congress Network
a doctor writes notes
News
Subcutaneous Olanzapine Long-Acting Injection Meets Efficacy Endpoint in Phase 3 Trial
06/25/2024
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational, once-monthly, subcutaneous long-acting injection of olanzapine called TEV-‘749 met its primary endpoint in the efficacy portion of the phase 3 SOLARIS trial.
An investigational,...
06/25/2024
Psych Congress Network
Alzheimer and cognitive decline graphic
News
Novel AD Treatment Approach Shows Promise in First Human Trial
06/25/2024
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a phase 2a trial suggest that the first-in-class small molecule LM11A-31 slowed progression of pathophysiological features of mild to moderate Alzheimer disease (AD) over 26 weeks.
Exploratory outcomes from a...
06/25/2024
Psych Congress Network
ADHD Linked With Hiked Risk of Lewy Body Disease
News
ADHD Linked With Hiked Risk of Lewy Body Disease
06/25/2024
Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric...
Attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk of Lewy Body disease (LBD), according to results from a recent prospective observational cohort study published in The American Journal of Geriatric...
Attention-deficit/hyperactivity...
06/25/2024
Psych Congress Network
Lecanemab AD Treatment Could Have Low Eligibility
News
Lecanemab AD Treatment Could Have Low Eligibility Rate
06/19/2024
Evi Arthur
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently FDA-approved treatment for Alzheimer disease (AD) may have a low eligibility rate (6.2%) among patients aged 70-89 years, according to recent results published in the journal Neurology. 
Lecanemab, a recently...
06/19/2024
Neurology
A doctor takes notes on paper on a clipboard sitting on a desk
News
Third Xanomeline-Trospium Trial Shows Improvement in Schizophrenia Symptoms
06/18/2024
Jolynn Tumolo
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was efficacious and well-tolerated in adults with schizophrenia experiencing acute psychosis, according to trial results published in JAMA Psychiatry. “In the phase 3 EMERGENT-3 trial in people with...
Xanomeline-trospium chloride was...
06/18/2024
Psych Congress Network
Young woman sleeping
News
Adolescents With Higher Adiposity More Vulnerable to Cognitive Impairments From Poor Sleep
06/13/2024
Meagan Thistle
Adolescents with higher levels of adiposity may be more susceptible to the cognitive effects of sleep restriction than those with lower adiposity, according to a recent single-blind randomized crossover trial.
Adolescents with higher levels of adiposity may be more susceptible to the cognitive effects of sleep restriction than those with lower adiposity, according to a recent single-blind randomized crossover trial.
Adolescents with higher levels...
06/13/2024
Neurology
News
Perimenopausal Patients at Significant Risk For Depression Emergence
06/13/2024
Brionna Mendoza
Compared to those in the pre-menopause phase, perimenopausal patients are at a higher risk for depressive symptoms and diagnoses. Results from the systematic review and meta-analysis were published in The Journal of Affective...
Compared to those in the pre-menopause phase, perimenopausal patients are at a higher risk for depressive symptoms and diagnoses. Results from the systematic review and meta-analysis were published in The Journal of Affective...
Compared to those in the...
06/13/2024
Psych Congress Network
Symptom Improvement Found Across Diagnoses With Placebo
News
Symptom Improvement Found Across Diagnoses With Placebo
06/12/2024
Evi Arthur
Placebo treatment was found to improve symptoms across multiple disorders, though the level of improvement varied from diagnosis to diagnosis, according to a systematic review and meta-analysis published in JAMA Psychiatry. 
Placebo treatment was found to improve symptoms across multiple disorders, though the level of improvement varied from diagnosis to diagnosis, according to a systematic review and meta-analysis published in JAMA Psychiatry. 
Placebo treatment was found to...
06/12/2024
Psych Congress Network

Advertisement

Exclusives

andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
chepke
Videos
Differential Diagnosis of Tardive Dyskinesia and Drug-Induced Parkinsonism
07/02/2024
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders such as drug-induced Parkinsonism.
Craig Chepke, MD, DFAPA, shares the importance of differentiating tardive dyskinesia (TD) from other movement disorders such as drug-induced Parkinsonism.
Craig Chepke, MD, DFAPA, shares...
07/02/2024
Psych Congress Network
Dr Rakesh Jain
Videos
Emerging Therapies in Bipolar Disorder Treatment
07/02/2024
Learn about the safety and efficacy of these new agents and gain insights into improving diagnosis and treatment strategies. 
Learn about the safety and efficacy of these new agents and gain insights into improving diagnosis and treatment strategies. 
Learn about the safety and...
07/02/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
Nishi Bhopal, MD
Q&As
Social Media Etiquette for Mental Health Clinicians
07/01/2024
Nishi Bhopal, MD, explains how to maintain professionalism while using social media to promote one'e telehealth practice.
Nishi Bhopal, MD, explains how to maintain professionalism while using social media to promote one'e telehealth practice.
Nishi Bhopal, MD, explains how...
07/01/2024
Psych Congress Network
Illustration of two women talking
SPONSORED VIDEO
Real Adult ADHD Patient Video
06/28/2024
Listen to Megan, an adult with ADHD, and her best friend talk about her ADHD journey, including current treatment with a nonstimulant medication.
Listen to Megan, an adult with ADHD, and her best friend talk about her ADHD journey, including current treatment with a nonstimulant medication.
Listen to Megan, an adult with...
06/28/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
Dr Jain
Videos
Navigating Cardiometabolic Symptoms With Conventional Bipolar Disorder Therapies
06/18/2024

With Rakesh Jain, MD

With Rakesh Jain, MD
In this video, Dr Jain discusses possible cardiometabolic symptoms that can occur in bipolar disorder treatment and how clinicians can avoid them from the start.
In this video, Dr Jain discusses possible cardiometabolic symptoms that can occur in bipolar disorder treatment and how clinicians can avoid them from the start.
In this video, Dr Jain discusses...
06/18/2024
Psych Congress Network
Key Challenges in Accurately Diagnosing Bipolar Disorder
Videos
Key Challenges in Accurately Diagnosing Bipolar Disorder
06/10/2024

Featuring Rakesh Jain, MD

Featuring Rakesh Jain, MD
Dr Jain discusses diagnosing and differentiating bipolar disorder from other mental health conditions, the importance of a thorough patient history, and more!
Dr Jain discusses diagnosing and differentiating bipolar disorder from other mental health conditions, the importance of a thorough patient history, and more!
Dr Jain discusses diagnosing and...
06/10/2024
Psych Congress Network
Lenard A. Adler, MD
Q&As
The Role of Telehealth in Rising ADHD Diagnosis Rates
06/07/2024

Featuring Lenard A. Adler, MD

Featuring Lenard A. Adler, MD
With the COVID-19 pandemic, telehealth emerged as a crucial tool, allowing remote patient consultations for safety and accessibility. Some argue it also drove the increase in adult ADHD diagnosis. Psych Congress Network sat down with...
With the COVID-19 pandemic, telehealth emerged as a crucial tool, allowing remote patient consultations for safety and accessibility. Some argue it also drove the increase in adult ADHD diagnosis. Psych Congress Network sat down with...
With the COVID-19 pandemic,...
06/07/2024
Psych Congress Network
Kevin Williams, MS, MPAS, PA-C
Videos
Helping Patients Navigate Psychopharmacological and Social Challenges in Tardive Dyskinesia
06/05/2024

Featuring Kevin Williams, MS, MPAS, PA-C

Featuring Kevin Williams, MS, MPAS, P...
Kevin Williams, MS, MPAS, PA-C, Psych Congress Steering Committee Member, at the 2024 NP Institute, Nurse Williams details how clinicians can more closely incorporate caregivers into patient treatment plans.
Kevin Williams, MS, MPAS, PA-C, Psych Congress Steering Committee Member, at the 2024 NP Institute, Nurse Williams details how clinicians can more closely incorporate caregivers into patient treatment plans.
Kevin Williams, MS, MPAS, PA-C,...
06/05/2024
Psych Congress Network

Refresher Quizzes

FDA
Quiz
What were the FDA's preliminary findings after investigating GLP-1 RAs?
04/25/2024
Do you remember this FDA update?
Do you remember this FDA update?
Do you remember this FDA update?
04/25/2024
Psych Congress Network
A cartoon illustration of a brain with two medical professionals standing on either side; one holds up a magnifying glass to the brain
Quiz
Differences in ADHD Symptoms Due to Sex
07/02/2024
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR says on this topic? Find out with this quiz!
Do you know what the DSM-5-TR...
07/02/2024
Psych Congress Network
quiz
Quiz
Which factor is NOT consideration when choosing an antidepressant medication?
06/28/2024
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a consideration when choosing an antidepressant medication according to the APA's major depressive disorder practice guidelines? Take the quiz to find out!
Which factor is NOT a...
06/28/2024
Psych Congress Network
quiz
Quiz
Which symptoms of schizophrenia must be present to make a diagnosis?
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
an illustrated head in profile with brain, against a pink background.
Quiz
DSM-5-TR: Opioid-Induced Mental Disorders
06/18/2024
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the test with this quiz!
Put your OUD knowledge to the...
06/18/2024
Psych Congress Network
Can stimulant use increase risk of heart damage in young adults with ADHD?
Quiz
Can stimulant use increase risk of heart damage in young adults with ADHD?
06/17/2024
Time for a pop quiz!
Time for a pop quiz!
Time for a pop quiz!
06/17/2024
Psych Congress Network
Risk of developing CUD is highest before what age?
Quiz
Risk of developing CUD is highest before what age?
06/14/2024
Do you remember this study?
Do you remember this study?
Do you remember this study?
06/14/2024
Psych Congress Network
By how much does olanzapine/samidorphan reduce weight gain risk in bipolar disorder treatment?
Expert Insights Quiz
By how much does olanzapine/samidorphan reduce weight gain risk in bipolar disorder treatment?
06/12/2024
Test your pharmacological knowledge!
Test your pharmacological knowledge!
Test your pharmacological...
06/12/2024
Psych Congress Network
A clock sits on a desk beside a pencil and scantron.
Quiz
Strategies to Ensure Continuity of Care in Tardive Dyskinesia
06/10/2024
Test your clinical knowledge with this quiz!
Test your clinical knowledge with this quiz!
Test your clinical knowledge...
06/10/2024
Psych Congress Network
A clock sits on a desk beside a pencil and scantron.
Quiz
Strategies to Ensure Continuity of Care in Tardive Dyskinesia
06/10/2024
Test your clinical knowledge with this quiz!
Test your clinical knowledge with this quiz!
Test your clinical knowledge...
06/10/2024
Psych Congress Network
What is best approach for interviewing patients with AUD on past habits?
Quiz
What is best approach for interviewing patients with AUD on past habits?
06/03/2024
Test your knowledge on APA guidelines
Test your knowledge on APA guidelines
Test your knowledge on APA...
06/03/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Recent Stories

Video Game Treatment for Adults With ADHD Cleared by FDA
News
Video Game Treatment for Adults With ADHD Cleared by FDA
07/02/2024
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults with primarily inattentive or combined-type ADHD who have a demonstrated attention issue.
AKL-T01 is indicated for adults...
07/02/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
News
FDA Approves First Liquid, Non-Stimulant for Pediatric ADHD
06/11/2024
Evi Arthur
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma, Inc.’s ONYDA™ XR (clonidine hydrochloride), a once-daily extended-release oral suspension medication, for the treatment of ADHD in patients 6 years and older.
The FDA approved Tris Pharma,...
06/11/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
Meagan Thistle
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement